Review



bcl xl sirna h  (Santa Cruz Biotechnology)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 88
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology bcl xl sirna h
    <t>BCL-xL</t> antagonism potentiates regorafenib activity on liver cancer cells. ( A , B ) Hep3B and HepG2 cells were treated for 16 h with the BCL-xL inhibitor A-1331852 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( C , D ) Hep3B and HepG2 cells were treated for 16 h with the BCL-2 inhibitor ABT-199 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( E ) Hep3B cells were transfected with siRNA control or against BCL-xL and BCL-2 and after 48 h treated with regorafenib at different concentrations, and cell viability was quantified by MTT. ( F ) RNA interference was confirmed and protein levels of BCL-xL, BCL-2, and β-actin are shown in parallel panels. (n = 3) * p < 0.05 vs. control or siCTRL cells.
    Bcl Xl Sirna H, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcl xl sirna h/product/Santa Cruz Biotechnology
    Average 88 stars, based on 1 article reviews
    bcl xl sirna h - by Bioz Stars, 2025-05
    88/100 stars

    Images

    1) Product Images from "Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models"

    Article Title: Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

    Journal: Cancers

    doi: 10.3390/cancers12020332

    BCL-xL antagonism potentiates regorafenib activity on liver cancer cells. ( A , B ) Hep3B and HepG2 cells were treated for 16 h with the BCL-xL inhibitor A-1331852 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( C , D ) Hep3B and HepG2 cells were treated for 16 h with the BCL-2 inhibitor ABT-199 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( E ) Hep3B cells were transfected with siRNA control or against BCL-xL and BCL-2 and after 48 h treated with regorafenib at different concentrations, and cell viability was quantified by MTT. ( F ) RNA interference was confirmed and protein levels of BCL-xL, BCL-2, and β-actin are shown in parallel panels. (n = 3) * p < 0.05 vs. control or siCTRL cells.
    Figure Legend Snippet: BCL-xL antagonism potentiates regorafenib activity on liver cancer cells. ( A , B ) Hep3B and HepG2 cells were treated for 16 h with the BCL-xL inhibitor A-1331852 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( C , D ) Hep3B and HepG2 cells were treated for 16 h with the BCL-2 inhibitor ABT-199 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( E ) Hep3B cells were transfected with siRNA control or against BCL-xL and BCL-2 and after 48 h treated with regorafenib at different concentrations, and cell viability was quantified by MTT. ( F ) RNA interference was confirmed and protein levels of BCL-xL, BCL-2, and β-actin are shown in parallel panels. (n = 3) * p < 0.05 vs. control or siCTRL cells.

    Techniques Used: Activity Assay, Transfection

    MCL-1 inhibition sensitizes hepatoma cells to the BCL-xL inhibitor A-1331852. ( A ) Representative Western blot images of MCL-1, BCL-xL, BIM, BCL-2, BAX, BAK, and β-Actin exhibited by Hep3B and HepG2 cells at different times (0–16 h) after regorafenib treatment (5 µM). ( B ) Effect of the MCL-1 inhibitor A-1210477 on Hep3B cells and HepG2 cells treated with A-1331852 ( A , 0.05, 0.1, or 0.2 µM) for 24 h. * p < 0.05 vs. control cells. ( C ) Hep3B spheroids were seeded and after 24 h of aggregation treated with vehicle, regorafenib (R, 2.5 μM), and/or A-1331852 (A, 0.1 or 0.2 µM) for seven days. Spheroid growth was monitored daily (scale bar, 500 µm). (n = 3) * p < 0.05 vs. control cells, # p < 0.05 vs. regorafenib-treated cells.
    Figure Legend Snippet: MCL-1 inhibition sensitizes hepatoma cells to the BCL-xL inhibitor A-1331852. ( A ) Representative Western blot images of MCL-1, BCL-xL, BIM, BCL-2, BAX, BAK, and β-Actin exhibited by Hep3B and HepG2 cells at different times (0–16 h) after regorafenib treatment (5 µM). ( B ) Effect of the MCL-1 inhibitor A-1210477 on Hep3B cells and HepG2 cells treated with A-1331852 ( A , 0.05, 0.1, or 0.2 µM) for 24 h. * p < 0.05 vs. control cells. ( C ) Hep3B spheroids were seeded and after 24 h of aggregation treated with vehicle, regorafenib (R, 2.5 μM), and/or A-1331852 (A, 0.1 or 0.2 µM) for seven days. Spheroid growth was monitored daily (scale bar, 500 µm). (n = 3) * p < 0.05 vs. control cells, # p < 0.05 vs. regorafenib-treated cells.

    Techniques Used: Inhibition, Western Blot

    BCL-xL inhibitor A-1331852 remarkably reduced tumor growth in regorafenib-treated PDXs. ( A , B ), Subcutaneous growth quantification and images of BCLC9 tumors in mice treated with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 4 weeks (n = 4–6). * p < 0.05 vs. vehicle-treated mice. ( C ) Representative images of PCNA expression in tumor samples from BCLC9 PDXs and quantification (scale bar, 50 µm). ( D ) Transcriptomic analysis of cell death-related genes in BCLC9 tumors from nude mice treated with vehicle, regorafenib, and/or A-1331852. (n = 2).
    Figure Legend Snippet: BCL-xL inhibitor A-1331852 remarkably reduced tumor growth in regorafenib-treated PDXs. ( A , B ), Subcutaneous growth quantification and images of BCLC9 tumors in mice treated with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 4 weeks (n = 4–6). * p < 0.05 vs. vehicle-treated mice. ( C ) Representative images of PCNA expression in tumor samples from BCLC9 PDXs and quantification (scale bar, 50 µm). ( D ) Transcriptomic analysis of cell death-related genes in BCLC9 tumors from nude mice treated with vehicle, regorafenib, and/or A-1331852. (n = 2).

    Techniques Used: Expressing

    Regorafenib-resistant HepG2 cells, exhibiting mRNA changes in BCL-xL and MCL-1, are re-sensitized to regorafenib by A-1331582. ( A ) Representative Western blot images of MCL-1, BCL-xL, BCL-2, BIM, and β-Actin protein levels in S and R HepG2 cells. * p < 0.05 vs. sensitive cells. ( B ) Effect of A-1331852 (A, 0.01 or 0.1 µM) on S and R HepG2 cells. * p < 0.05 vs. control cells. ( C ) Subcutaneous growth of R HepG2 cells in mice treated orally with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 2 weeks (n = 4). ( D ) Representative images of PCNA expression in tumors from HepG2 R CDXs (scale bar, 100 µm). * p < 0.05 vs. vehicle-treated mice.
    Figure Legend Snippet: Regorafenib-resistant HepG2 cells, exhibiting mRNA changes in BCL-xL and MCL-1, are re-sensitized to regorafenib by A-1331582. ( A ) Representative Western blot images of MCL-1, BCL-xL, BCL-2, BIM, and β-Actin protein levels in S and R HepG2 cells. * p < 0.05 vs. sensitive cells. ( B ) Effect of A-1331852 (A, 0.01 or 0.1 µM) on S and R HepG2 cells. * p < 0.05 vs. control cells. ( C ) Subcutaneous growth of R HepG2 cells in mice treated orally with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 2 weeks (n = 4). ( D ) Representative images of PCNA expression in tumors from HepG2 R CDXs (scale bar, 100 µm). * p < 0.05 vs. vehicle-treated mice.

    Techniques Used: Western Blot, Expressing

    Alterations in BCL-xL mRNA levels and BCL-xL/MCL-1 ratio in HCC patients. ( A ) BCL-xL and ( B ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in healthy liver (n = 10) and in cirrhotic and tumoral tissue from HCC patients (n = 12) with Hepatitis C virus (HCV) and/or Ethanol (EtOH etiology. * p < 0.05 vs. control. ( C ) BCL-xL and ( D ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in a commercial mRNA array with healthy liver (n = 8) and tumoral tissue from HCC patients in different stages (I-II, n = 14; IIIA-IV, n = 12). ( E , F ) Representation of survival probability depending on BCL-xL expression (blue, high; purple, low) in patients with liver and colorectal cancer, respectively.
    Figure Legend Snippet: Alterations in BCL-xL mRNA levels and BCL-xL/MCL-1 ratio in HCC patients. ( A ) BCL-xL and ( B ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in healthy liver (n = 10) and in cirrhotic and tumoral tissue from HCC patients (n = 12) with Hepatitis C virus (HCV) and/or Ethanol (EtOH etiology. * p < 0.05 vs. control. ( C ) BCL-xL and ( D ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in a commercial mRNA array with healthy liver (n = 8) and tumoral tissue from HCC patients in different stages (I-II, n = 14; IIIA-IV, n = 12). ( E , F ) Representation of survival probability depending on BCL-xL expression (blue, high; purple, low) in patients with liver and colorectal cancer, respectively.

    Techniques Used: Expressing



    Similar Products

    bcl xl sirna h  (Santa Cruz Biotechnology)
    88
    Santa Cruz Biotechnology bcl xl sirna h
    <t>BCL-xL</t> antagonism potentiates regorafenib activity on liver cancer cells. ( A , B ) Hep3B and HepG2 cells were treated for 16 h with the BCL-xL inhibitor A-1331852 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( C , D ) Hep3B and HepG2 cells were treated for 16 h with the BCL-2 inhibitor ABT-199 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( E ) Hep3B cells were transfected with siRNA control or against BCL-xL and BCL-2 and after 48 h treated with regorafenib at different concentrations, and cell viability was quantified by MTT. ( F ) RNA interference was confirmed and protein levels of BCL-xL, BCL-2, and β-actin are shown in parallel panels. (n = 3) * p < 0.05 vs. control or siCTRL cells.
    Bcl Xl Sirna H, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcl xl sirna h/product/Santa Cruz Biotechnology
    Average 88 stars, based on 1 article reviews
    bcl xl sirna h - by Bioz Stars, 2025-05
    88/100 stars
    		  Buy from Supplier

    Image Search Results


    BCL-xL antagonism potentiates regorafenib activity on liver cancer cells. ( A , B ) Hep3B and HepG2 cells were treated for 16 h with the BCL-xL inhibitor A-1331852 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( C , D ) Hep3B and HepG2 cells were treated for 16 h with the BCL-2 inhibitor ABT-199 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( E ) Hep3B cells were transfected with siRNA control or against BCL-xL and BCL-2 and after 48 h treated with regorafenib at different concentrations, and cell viability was quantified by MTT. ( F ) RNA interference was confirmed and protein levels of BCL-xL, BCL-2, and β-actin are shown in parallel panels. (n = 3) * p < 0.05 vs. control or siCTRL cells.

    Journal: Cancers

    Article Title: Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

    doi: 10.3390/cancers12020332

    Figure Lengend Snippet: BCL-xL antagonism potentiates regorafenib activity on liver cancer cells. ( A , B ) Hep3B and HepG2 cells were treated for 16 h with the BCL-xL inhibitor A-1331852 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( C , D ) Hep3B and HepG2 cells were treated for 16 h with the BCL-2 inhibitor ABT-199 and regorafenib at different concentrations, and cell viability was quantified by MTT. ( E ) Hep3B cells were transfected with siRNA control or against BCL-xL and BCL-2 and after 48 h treated with regorafenib at different concentrations, and cell viability was quantified by MTT. ( F ) RNA interference was confirmed and protein levels of BCL-xL, BCL-2, and β-actin are shown in parallel panels. (n = 3) * p < 0.05 vs. control or siCTRL cells.

    Article Snippet: BCL-2 siRNA (h) (sc-29214), BCL-xL siRNA (h) (sc-43630), and scrambled controls were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), while a second siRNA for BCL-2 (ID#s1915) and for BCL-xL (ID#s1920) were obtained from Ambion Life technologies (Carlsbad, CA, USA).

    Techniques: Activity Assay, Transfection

    MCL-1 inhibition sensitizes hepatoma cells to the BCL-xL inhibitor A-1331852. ( A ) Representative Western blot images of MCL-1, BCL-xL, BIM, BCL-2, BAX, BAK, and β-Actin exhibited by Hep3B and HepG2 cells at different times (0–16 h) after regorafenib treatment (5 µM). ( B ) Effect of the MCL-1 inhibitor A-1210477 on Hep3B cells and HepG2 cells treated with A-1331852 ( A , 0.05, 0.1, or 0.2 µM) for 24 h. * p < 0.05 vs. control cells. ( C ) Hep3B spheroids were seeded and after 24 h of aggregation treated with vehicle, regorafenib (R, 2.5 μM), and/or A-1331852 (A, 0.1 or 0.2 µM) for seven days. Spheroid growth was monitored daily (scale bar, 500 µm). (n = 3) * p < 0.05 vs. control cells, # p < 0.05 vs. regorafenib-treated cells.

    Journal: Cancers

    Article Title: Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

    doi: 10.3390/cancers12020332

    Figure Lengend Snippet: MCL-1 inhibition sensitizes hepatoma cells to the BCL-xL inhibitor A-1331852. ( A ) Representative Western blot images of MCL-1, BCL-xL, BIM, BCL-2, BAX, BAK, and β-Actin exhibited by Hep3B and HepG2 cells at different times (0–16 h) after regorafenib treatment (5 µM). ( B ) Effect of the MCL-1 inhibitor A-1210477 on Hep3B cells and HepG2 cells treated with A-1331852 ( A , 0.05, 0.1, or 0.2 µM) for 24 h. * p < 0.05 vs. control cells. ( C ) Hep3B spheroids were seeded and after 24 h of aggregation treated with vehicle, regorafenib (R, 2.5 μM), and/or A-1331852 (A, 0.1 or 0.2 µM) for seven days. Spheroid growth was monitored daily (scale bar, 500 µm). (n = 3) * p < 0.05 vs. control cells, # p < 0.05 vs. regorafenib-treated cells.

    Article Snippet: BCL-2 siRNA (h) (sc-29214), BCL-xL siRNA (h) (sc-43630), and scrambled controls were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), while a second siRNA for BCL-2 (ID#s1915) and for BCL-xL (ID#s1920) were obtained from Ambion Life technologies (Carlsbad, CA, USA).

    Techniques: Inhibition, Western Blot

    BCL-xL inhibitor A-1331852 remarkably reduced tumor growth in regorafenib-treated PDXs. ( A , B ), Subcutaneous growth quantification and images of BCLC9 tumors in mice treated with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 4 weeks (n = 4–6). * p < 0.05 vs. vehicle-treated mice. ( C ) Representative images of PCNA expression in tumor samples from BCLC9 PDXs and quantification (scale bar, 50 µm). ( D ) Transcriptomic analysis of cell death-related genes in BCLC9 tumors from nude mice treated with vehicle, regorafenib, and/or A-1331852. (n = 2).

    Journal: Cancers

    Article Title: Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

    doi: 10.3390/cancers12020332

    Figure Lengend Snippet: BCL-xL inhibitor A-1331852 remarkably reduced tumor growth in regorafenib-treated PDXs. ( A , B ), Subcutaneous growth quantification and images of BCLC9 tumors in mice treated with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 4 weeks (n = 4–6). * p < 0.05 vs. vehicle-treated mice. ( C ) Representative images of PCNA expression in tumor samples from BCLC9 PDXs and quantification (scale bar, 50 µm). ( D ) Transcriptomic analysis of cell death-related genes in BCLC9 tumors from nude mice treated with vehicle, regorafenib, and/or A-1331852. (n = 2).

    Article Snippet: BCL-2 siRNA (h) (sc-29214), BCL-xL siRNA (h) (sc-43630), and scrambled controls were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), while a second siRNA for BCL-2 (ID#s1915) and for BCL-xL (ID#s1920) were obtained from Ambion Life technologies (Carlsbad, CA, USA).

    Techniques: Expressing

    Regorafenib-resistant HepG2 cells, exhibiting mRNA changes in BCL-xL and MCL-1, are re-sensitized to regorafenib by A-1331582. ( A ) Representative Western blot images of MCL-1, BCL-xL, BCL-2, BIM, and β-Actin protein levels in S and R HepG2 cells. * p < 0.05 vs. sensitive cells. ( B ) Effect of A-1331852 (A, 0.01 or 0.1 µM) on S and R HepG2 cells. * p < 0.05 vs. control cells. ( C ) Subcutaneous growth of R HepG2 cells in mice treated orally with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 2 weeks (n = 4). ( D ) Representative images of PCNA expression in tumors from HepG2 R CDXs (scale bar, 100 µm). * p < 0.05 vs. vehicle-treated mice.

    Journal: Cancers

    Article Title: Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

    doi: 10.3390/cancers12020332

    Figure Lengend Snippet: Regorafenib-resistant HepG2 cells, exhibiting mRNA changes in BCL-xL and MCL-1, are re-sensitized to regorafenib by A-1331582. ( A ) Representative Western blot images of MCL-1, BCL-xL, BCL-2, BIM, and β-Actin protein levels in S and R HepG2 cells. * p < 0.05 vs. sensitive cells. ( B ) Effect of A-1331852 (A, 0.01 or 0.1 µM) on S and R HepG2 cells. * p < 0.05 vs. control cells. ( C ) Subcutaneous growth of R HepG2 cells in mice treated orally with A-1331852 (25 mg/kg) and regorafenib (30 mg/kg) for 2 weeks (n = 4). ( D ) Representative images of PCNA expression in tumors from HepG2 R CDXs (scale bar, 100 µm). * p < 0.05 vs. vehicle-treated mice.

    Article Snippet: BCL-2 siRNA (h) (sc-29214), BCL-xL siRNA (h) (sc-43630), and scrambled controls were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), while a second siRNA for BCL-2 (ID#s1915) and for BCL-xL (ID#s1920) were obtained from Ambion Life technologies (Carlsbad, CA, USA).

    Techniques: Western Blot, Expressing

    Alterations in BCL-xL mRNA levels and BCL-xL/MCL-1 ratio in HCC patients. ( A ) BCL-xL and ( B ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in healthy liver (n = 10) and in cirrhotic and tumoral tissue from HCC patients (n = 12) with Hepatitis C virus (HCV) and/or Ethanol (EtOH etiology. * p < 0.05 vs. control. ( C ) BCL-xL and ( D ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in a commercial mRNA array with healthy liver (n = 8) and tumoral tissue from HCC patients in different stages (I-II, n = 14; IIIA-IV, n = 12). ( E , F ) Representation of survival probability depending on BCL-xL expression (blue, high; purple, low) in patients with liver and colorectal cancer, respectively.

    Journal: Cancers

    Article Title: Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

    doi: 10.3390/cancers12020332

    Figure Lengend Snippet: Alterations in BCL-xL mRNA levels and BCL-xL/MCL-1 ratio in HCC patients. ( A ) BCL-xL and ( B ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in healthy liver (n = 10) and in cirrhotic and tumoral tissue from HCC patients (n = 12) with Hepatitis C virus (HCV) and/or Ethanol (EtOH etiology. * p < 0.05 vs. control. ( C ) BCL-xL and ( D ) BCL-xL/MCL-1 mRNA levels were measured by qPCR in a commercial mRNA array with healthy liver (n = 8) and tumoral tissue from HCC patients in different stages (I-II, n = 14; IIIA-IV, n = 12). ( E , F ) Representation of survival probability depending on BCL-xL expression (blue, high; purple, low) in patients with liver and colorectal cancer, respectively.

    Article Snippet: BCL-2 siRNA (h) (sc-29214), BCL-xL siRNA (h) (sc-43630), and scrambled controls were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), while a second siRNA for BCL-2 (ID#s1915) and for BCL-xL (ID#s1920) were obtained from Ambion Life technologies (Carlsbad, CA, USA).

    Techniques: Expressing